Ancestral library identifies conserved reprogrammable liver motif on AAV capsid

Li, 2020, Engineering adeno-associated virus vectors for gene therapy, Nat. Rev. Genet., 21, 255, 10.1038/s41576-019-0205-4 Keeler, 2019, Recombinant adeno-associated virus gene therapy in light of luxturna (and zolgensma and glybera): where are we, and how did we get here?, Annu. Rev. Virol., 6, 601, 10.1146/annurev-virology-092818-015530 Hudry, 2019, Therapeutic AAV gene transfer to the nervous system: a clinical reality, Neuron, 101, 839, 10.1016/j.neuron.2019.02.017 Mendell, 2021, Current clinical applications of in vivo gene therapy with AAVs, Mol. Ther., 29, 464, 10.1016/j.ymthe.2020.12.007 Manno, 2006, Successful transduction of liver in hemophilia by AAV-Factor IX and limitations imposed by the host immune response, Nat. Med., 12, 342, 10.1038/nm1358 Nathwani, 2011, Adenovirus-associated virus vector-mediated gene transfer in hemophilia B, N. Engl. J. Med., 365, 2357, 10.1056/NEJMoa1108046 Day, 2021, Onasemnogene abeparvovec gene therapy for symptomatic infantile-onset spinal muscular atrophy in patients with two copies of SMN2 (STR1VE): an open-label, single-arm, multicentre, phase 3 trial, Lancet Neurol., 20, 284, 10.1016/S1474-4422(21)00001-6 Philippidis, 2020, After third death, audentes' AT132 remains on clinical hold, Hum. Gene Ther., 31, 908, 10.1089/hum.2020.29133.bfs Pulicherla, 2011, Engineering liver-detargeted AAV9 vectors for cardiac and musculoskeletal gene transfer, Mol. Ther., 19, 1070, 10.1038/mt.2011.22 Wang, 2018, A rationally engineered capsid variant of AAV9 for systemic CNS-directed and peripheral tissue-detargeted gene delivery in neonates, Mol. Ther. Methods Clin. Dev., 9, 234, 10.1016/j.omtm.2018.03.004 Rotundo, 2013, Use of a lower dosage liver-detargeted AAV vector to prevent hamster muscular dystrophy, Hum. Gene Ther., 24, 424, 10.1089/hum.2012.121 Gao, 2005, New recombinant serotypes of AAV vectors, Curr. Gene Ther., 5, 285, 10.2174/1566523054065057 Grimm, 2006, Liver transduction with recombinant adeno-associated virus is primarily restricted by capsid serotype not vector genotype, J. Virol., 80, 426, 10.1128/JVI.80.1.426-439.2006 Nakai, 2005, Unrestricted hepatocyte transduction with adeno-associated virus serotype 8 vectors in mice, J. Virol., 79, 214, 10.1128/JVI.79.1.214-224.2005 Vandenberghe, 2009, Naturally occurring singleton residues in AAV capsid impact vector performance and illustrate structural constraints, Gene Ther., 16, 1416, 10.1038/gt.2009.101 Wu, 2006, Single amino acid changes can influence titer, heparin binding, and tissue tropism in different adeno-associated virus serotypes, J. Virol., 80, 11393, 10.1128/JVI.01288-06 Vandenberghe, 2006, Heparin binding directs activation of T cells against adeno-associated virus serotype 2 capsid, Nat. Med., 12, 967, 10.1038/nm1445 Zhong, 2008, Next generation of adeno-associated virus 2 vectors: point mutations in tyrosines lead to high-efficiency transduction at lower doses, Proc. Natl. Acad. Sci. USA, 105, 7827, 10.1073/pnas.0802866105 Xie, 2002, The atomic structure of adeno-associated virus (AAV-2), a vector for human gene therapy, Proc. Natl. Acad. Sci. USA, 99, 10405, 10.1073/pnas.162250899 Nam, 2007, Structure of adeno-associated virus serotype 8, a gene therapy vector, J. Virol., 81, 12260, 10.1128/JVI.01304-07 Opie, 2003, Identification of amino acid residues in the capsid proteins of adeno-associated virus type 2 that contribute to heparan sulfate proteoglycan binding, J. Virol., 77, 6995, 10.1128/JVI.77.12.6995-7006.2003 Kern, 2003, Identification of a heparin-binding motif on adeno-associated virus type 2 capsids, J. Virol., 77, 11072, 10.1128/JVI.77.20.11072-11081.2003 Asokan, 2010, Reengineering a receptor footprint of adeno-associated virus enables selective and systemic gene transfer to muscle, Nat. Biotechnol., 28, 79, 10.1038/nbt.1599 Shen, 2013, Engraftment of a galactose receptor footprint onto adeno-associated viral capsids improves transduction efficiency, J. Biol. Chem., 288, 28814, 10.1074/jbc.M113.482380 Maurer, 2018, The assembly-activating protein promotes stability and interactions between AAV's viral proteins to nucleate capsid assembly, Cell Rep., 23, 1817, 10.1016/j.celrep.2018.04.026 Dudek, 2020, GPR108 is a highly conserved AAV entry factor, Mol. Ther., 28, 367, 10.1016/j.ymthe.2019.11.005 Grimm, 2008, In vitro and in vivo gene therapy vector evolution via multispecies interbreeding and retargeting of adeno-associated viruses, J. Virol., 82, 5887, 10.1128/JVI.00254-08 Dalkara, 2013, In vivo-directed evolution of a new adeno-associated virus for therapeutic outer retinal gene delivery from the vitreous, Sci. Transl. Med., 5, 189ra76, 10.1126/scitranslmed.3005708 Lisowski, 2014, Selection and evaluation of clinically relevant AAV variants in a xenograft liver model, Nature, 506, 382, 10.1038/nature12875 Deverman, 2016, Cre-dependent selection yields AAV variants for widespread gene transfer to the adult brain, Nat. Biotechnol., 34, 204, 10.1038/nbt.3440 Hordeaux, 2018, The neurotropic properties of AAV-PHP.B are limited to C57BL/6J mice, Mol. Ther., 26, 664, 10.1016/j.ymthe.2018.01.018 Hordeaux, 2019, The GPI-linked protein LY6A drives AAV-PHP.B transport across the blood-brain barrier, Mol. Ther., 27, 912, 10.1016/j.ymthe.2019.02.013 Huang, 2019, Delivering genes across the blood-brain barrier: LY6A, a novel cellular receptor for AAV-PHP.B capsids, PLoS One, 14, 10.1371/journal.pone.0225206 Ramachandran, 2017, Evaluation of dose and safety of AAV7m8 and AAV8BP2 in the non-human primate retina, Hum. Gene Ther., 28, 154, 10.1089/hum.2016.111 Paulk, 2018, Bioengineered viral platform for intramuscular passive vaccine delivery to human skeletal muscle, Mol. Ther. Methods Clin. Dev., 10, 144, 10.1016/j.omtm.2018.06.001 Paulk, 2018, Bioengineered AAV capsids with combined high human liver transduction in vivo and unique humoral seroreactivity, Mol. Ther., 26, 289, 10.1016/j.ymthe.2017.09.021 Marsic, 2014, Vector design Tour de Force: integrating combinatorial and rational approaches to derive novel adeno-associated virus variants, Mol. Ther., 22, 1900, 10.1038/mt.2014.139 Havlik, 2020, Coevolution of adeno-associated virus capsid antigenicity and tropism through a structure-guided approach, J. Virol., 94, 10.1128/JVI.00976-20 Albright, 2018, Mapping the structural determinants required for AAVrh.10 transport across the blood-brain barrier, Mol. Ther., 26, 510, 10.1016/j.ymthe.2017.10.017 Zinn, 2015, In silico reconstruction of the viral evolutionary lineage yields a potent gene therapy vector, Cell Rep., 12, 1056, 10.1016/j.celrep.2015.07.019 Wong, 2016, Multiplexed barcoded CRISPR-Cas9 screening enabled by CombiGEM, Proc. Natl. Acad. Sci. USA, 113, 2544, 10.1073/pnas.1517883113 Wong, 2015, Massively parallel high-order combinatorial genetics in human cells, Nat. Biotechnol., 33, 952, 10.1038/nbt.3326 Adachi, 2014, Drawing a high-resolution functional map of adeno-associated virus capsid by massively parallel sequencing, Nat. Commun., 5, 3075, 10.1038/ncomms4075 Ogden, 2019, Comprehensive AAV capsid fitness landscape reveals a viral gene and enables machine-guided design, Science, 366, 1139, 10.1126/science.aaw2900 Weinmann, 2020, Identification of a myotropic AAV by massively parallel in vivo evaluation of barcoded capsid variants, Nat. Commun., 11, 5432, 10.1038/s41467-020-19230-w Brown, 2021, Deep parallel characterization of AAV tropism and AAV-mediated transcriptional changes via single-cell RNA sequencing, Front. Immunol., 12, 730825, 10.3389/fimmu.2021.730825 Davidsson, 2019, A systematic capsid evolution approach performed in vivo for the design of AAV vectors with tailored properties and tropism, Proc. Natl. Acad. Sci. USA, 116, 27053, 10.1073/pnas.1910061116 Goertsen, 2022, AAV capsid variants with brain-wide transgene expression and decreased liver targeting after intravenous delivery in mouse and marmoset, Nat. Neurosci., 25, 106, 10.1038/s41593-021-00969-4 Öztürk, 2021, scAAVengr, a transcriptome-based pipeline for quantitative ranking of engineered AAVs with single-cell resolution, Elife, 10, 10.7554/eLife.64175 Ellis, 2013, A survey of ex vivo/in vitro transduction efficiency of mammalian primary cells and cell lines with Nine natural adeno-associated virus (AAV1-9) and one engineered adeno-associated virus serotype, Virol. J., 10, 74, 10.1186/1743-422X-10-74 Thomas, 2004, Rapid uncoating of vector genomes is the key to efficient liver transduction with pseudotyped adeno-associated virus vectors, J. Virol., 78, 3110, 10.1128/JVI.78.6.3110-3122.2004 Wang, 2015, Comparative study of liver gene transfer with AAV vectors based on natural and engineered AAV capsids, Mol. Ther., 23, 1877, 10.1038/mt.2015.179 Landegger, 2017, A synthetic AAV vector enables safe and efficient gene transfer to the mammalian inner ear, Nat. Biotechnol., 35, 280, 10.1038/nbt.3781 Ikeda, 2018, Efficient gene transfer to kidney mesenchymal cells using a synthetic adeno-associated viral vector, J. Am. Soc. Nephrol., 29, 2287, 10.1681/ASN.2018040426 Carvalho, 2018, Synthetic adeno-associated viral vector efficiently targets mouse and nonhuman primate retina in vivo, Hum. Gene Ther., 29, 771, 10.1089/hum.2017.154 Hudry, 2018, Efficient gene transfer to the central nervous system by single-stranded Anc80L65, Mol. Ther. Methods Clin. Dev., 10, 197, 10.1016/j.omtm.2018.07.006 Wu, 2000, Mutational analysis of the adeno-associated virus type 2 (AAV2) capsid gene and construction of AAV2 vectors with altered tropism, J. Virol., 74, 8635, 10.1128/JVI.74.18.8635-8647.2000 Lochrie, 2006, Mutations on the external surfaces of adeno-associated virus type 2 capsids that affect transduction and neutralization, J. Virol., 80, 821, 10.1128/JVI.80.2.821-834.2006 Guo, 2004, Protein tolerance to random amino acid change, Proc. Natl. Acad. Sci. USA, 101, 9205, 10.1073/pnas.0403255101 Schmit, 2020, Cross-packaging and capsid mosaic formation in multiplexed AAV libraries, Mol. Ther. Methods Clin. Dev., 17, 107, 10.1016/j.omtm.2019.11.014 Cabanes-Creus, 2021, Single amino acid insertion allows functional transduction of murine hepatocytes with human liver tropic AAV capsids, Mol. Ther. Methods Clin. Dev., 21, 607, 10.1016/j.omtm.2021.04.010 Lerch, 2010, The structure of adeno-associated virus serotype 3B (AAV-3B): insights into receptor binding and immune evasion, Virology, 403, 26, 10.1016/j.virol.2010.03.027 Govindasamy, 2006, Structurally mapping the diverse phenotype of adeno-associated virus serotype 4, J. Virol., 80, 11556, 10.1128/JVI.01536-06 Govindasamy, 2013, Structural insights into adeno-associated virus serotype 5, J. Virol., 87, 11187, 10.1128/JVI.00867-13 Xie, 2011, Structure–function analysis of receptor-binding in adeno-associated virus serotype 6 (AAV-6), Virology, 420, 10, 10.1016/j.virol.2011.08.011 DiMattia, 2012, Structural insight into the unique properties of adeno-associated virus serotype 9, J. Virol., 86, 6947, 10.1128/JVI.07232-11 Mikals, 2014, The structure of AAVrh32.33, a novel gene delivery vector, J. Struct. Biol., 186, 308, 10.1016/j.jsb.2014.03.020 Halder, 2015, Structure of neurotropic adeno-associated virus AAVrh.8, J. Struct. Biol., 192, 21, 10.1016/j.jsb.2015.08.017 Bryant, 2021, Deep diversification of an AAV capsid protein by machine learning, Nat. Biotechnol., 39, 691, 10.1038/s41587-020-00793-4 Pekrun, 2019, Using a barcoded AAV capsid library to select for clinically relevant gene therapy vectors, JCI Insight, 4, 131610, 10.1172/jci.insight.131610 Li, 2015, Efficient and targeted transduction of nonhuman primate liver with systemically delivered optimized AAV3B vectors, Mol. Ther., 23, 1867, 10.1038/mt.2015.174 Bevan, 2011, Systemic gene delivery in large species for targeting spinal cord, brain, and peripheral tissues for pediatric disorders, Mol. Ther., 19, 1971, 10.1038/mt.2011.157 Foust, 2010, Rescue of the spinal muscular atrophy phenotype in a mouse model by early postnatal delivery of SMN, Nat. Biotechnol., 28, 271, 10.1038/nbt.1610 Kornegay, 2010, Widespread muscle expression of an AAV9 human mini-dystrophin vector after intravenous injection in neonatal dystrophin-deficient dogs, Mol. Ther., 18, 1501, 10.1038/mt.2010.94 Hinderer, 2018, Severe toxicity in nonhuman primates and piglets following high-dose intravenous administration of an adeno-associated virus vector expressing human SMN, Hum. Gene Ther., 29, 285, 10.1089/hum.2018.015 Meyer, 2019, Structure of the gene therapy vector, adeno-associated virus with its cell receptor, Elife, 8, 10.7554/eLife.44707 Zhang, 2019, Adeno-associated virus 2 bound to its cellular receptor AAVR, Nat. Microbiol., 4, 675, 10.1038/s41564-018-0356-7 Dudek, 2018, An alternate route for adeno-associated virus (AAV) entry independent of AAV receptor, J. Virol., 92, 10.1128/JVI.02213-17 Pillay, 2016, An essential receptor for adeno-associated virus infection, Nature, 530, 108, 10.1038/nature16465 Kasai, 2018, HuH-7 reference genome profile: complex karyotype composed of massive loss of heterozygosity, Hum. Cell, 31, 261, 10.1007/s13577-018-0212-3 Wang, 2010, The pleiotropic effects of natural AAV infections on liver-directed gene transfer in macaques, Mol. Ther., 18, 126, 10.1038/mt.2009.245 Lock, 2010, Rapid, simple, and versatile manufacturing of recombinant adeno-associated viral vectors at scale, Hum. Gene Ther., 21, 1259, 10.1089/hum.2010.055 Sanmiguel, 2019, Quantitative and digital droplet-based AAV genome titration, Methods Mol. Biol., 1950, 51, 10.1007/978-1-4939-9139-6_4